조진균증 치료 시장 규모, 점유율, 성장 분석, 치료 유형별, 적응 질환별, 연령층별, 성별, 유통 채널별, 지역별 - 산업 예측(2024-2031년)

Global Onychomycosis Treatment Market size was valued at USD 4.52 billion in 2022 and is poised to grow from USD 4.91 billion in 2023 to USD 9.5 billion by 2031, growing at a CAGR of 8.60% during the forecast period (2024-2031).

The onychomycosis treatment market is witnessing significant growth driven by the increasing prevalence of nail fungal infections, advancements in treatment options, and heightened awareness about the condition. This market encompasses a variety of treatments, including topical solutions, laser therapies, and oral antifungal medications. Additionally, the rise in healthcare expenditure is enhancing accessibility to superior treatment alternatives, further fueling market expansion. However, challenges such as high treatment costs and potential side effects associated with certain therapies are constraining market momentum. Advanced treatments, particularly laser therapies and oral antifungals like itraconazole and terbinafine, may present financial barriers that deter patient uptake. Moreover, concerns over possible liver damage and gastrointestinal complications associated with these medications can contribute to patient reluctance. Despite these challenges, the market is poised for growth, bolstered by opportunities arising from innovations in drug development, including nanotechnology-driven products and enhanced drug delivery systems such as sustained-release formulations and highly efficacious topical treatments. As these innovations emerge, they hold the promise of improving patient outcomes and increasing the attractiveness of onychomycosis treatments in the healthcare landscape. Overall, the interplay of escalating demand and evolving therapeutic options suggests a dynamic future for the onychomycosis treatment market.

Top-down and bottom-up approaches were used to estimate and validate the size of the Global Onychomycosis Treatment market and to estimate the size of various other dependent submarkets. The research methodology used to estimate the market size includes the following details: The key players in the market were identified through secondary research, and their market shares in the respective regions were determined through primary and secondary research. This entire procedure includes the study of the annual and financial reports of the top market players and extensive interviews for key insights from industry leaders such as CEOs, VPs, directors, and marketing executives. All percentage shares split, and breakdowns were determined using secondary sources and verified through Primary sources. All possible parameters that affect the markets covered in this research study have been accounted for, viewed in extensive detail, verified through primary research, and analyzed to get the final quantitative and qualitative data.

Global Onychomycosis Treatment Market Segmental Analysis

Global Onychomycosis Treatment Market is segmented by Treatment Type, Disease Indication, Age Group, Gender, Distribution Channel, and region. Based on Treatment Type, the market is segmented into Drugs, Lasers, and Photodynamic Therapy. Based on Disease Indication, the market is segmented into Distal Subungual Onychomycosis, White Superficial Onychomycosis, Proximal Subungual Onychomycosis, Candidal Onychomycosis, and Total Dystrophic Onychomycosis. Based on Age Group, the market is segmented into 0 to 18 Years, 19 to 39 Years, 40 to 64 Years, and 65 Years & Above. Based on Gender, the market is segmented into Male, and Female. Based on Distribution Channel, the market is segmented into Institutional Sales, and Retail Sales. Based on region, the market is segmented into North America, Europe, Asia Pacific, Latin America and Middle East & and Africa.

Driver of the Global Onychomycosis Treatment Market

The Global Onychomycosis Treatment market is significantly driven by the increasing prevalence of fungal nail infections, largely attributed to an aging population, rising diabetes rates, and a higher incidence of immunocompromising conditions. As individuals age and comorbidities rise, the susceptibility to onychomycosis escalates, demanding effective treatment options. Additionally, heightened awareness among patients about fungal infections, coupled with improved diagnostic techniques and advanced treatment options being recognized by healthcare professionals, is leading to more accurate diagnoses and subsequent treatments. This confluence of factors not only curtails the stigma associated with fungal infections but also propels market growth as demand for effective therapies surges.

Restraints in the Global Onychomycosis Treatment Market

One prominent market restraint for the Global Onychomycosis Treatment market is the variability in treatment efficacy across diverse patient populations and infection profiles. Many available therapies may not deliver consistent results for all individuals, leading to a significant rate of recurrence, which can diminish patient trust and compliance. Furthermore, treatment effectiveness often hinges on the specific type and severity of the fungal infection, underscoring the imperative for ongoing research and development. This necessity for tailored solutions can hinder market growth, as healthcare providers grapple with the challenge of offering universally effective and reliable treatment options for onychomycosis.

Market Trends of the Global Onychomycosis Treatment Market

The global onychomycosis treatment market is witnessing a significant trend towards the adoption of advanced laser therapies, particularly Carbon Dioxide (CO2) and Blue Light lasers. CO2 lasers dominate this segment due to their ability to penetrate deeper into the nail bed, effectively targeting and eradicating stubborn fungal infections. Meanwhile, Blue Light therapies are gaining traction for treating mild cases or as adjunctive treatments, enhancing overall efficacy. With both modalities delivering heat energy to eliminate pathogens, the trend indicates a shift towards non-invasive, effective solutions, appealing to consumers seeking quick recovery with minimal side effects, thereby driving market growth and innovation.

Table of Contents

Introduction

• Objectives of the Study
• Definitions
• Market Scope

Research Methodology

• Information Procurement
• Secondary & Primary Data Sources
• Market Size Estimation
• Market Assumptions & Limitations

Executive Summary

• Market Overview Outlook
• Supply Demand Trend Analysis
• Segmental Opportunity Analysis

Market Dynamics & Outlook

• Market Dynamics
  • Drivers
  • Opportunities
  • Restraints
  • Challenges
• Porters Analysis
  • Competitive rivalry
  • Threat of Substitute Products
  • Bargaining Power of Buyers
  • Threat of New Entrants
  • Bargaining Power of Suppliers

Key Market Insights

• Technology Analysis
• Value Chain Analysis
• Ecosystem of the Market
• Case study Analysis
• Regulatory Landscape
• Innovation Matrix
• PESTEL Analysis
• Top Investment Analysis
• Key Success Factor
• Degree of Competition

Onychomycosis Treatment Market by Treatment Type

• Market Overview
• Drugs
  • Oral
  • RX
  • OTC
  • Tropical
  • RX
  • OTC
• Lasers
  • C02 Ablative Lasers
  • Nd: YAG Lasers
  • Dual-wavelength near-infrared Lasers
• Photodynamic Therapy

Onychomycosis Treatment Market by Disease Indication

• Market Overview
• Distal Subungual Onychomycosis
• White Superficial Onychomycosis
• Proximal Subungual Onychomycosis
• Candidal Onychomycosis
• Total Dystrophic Onychomycosis

Onychomycosis Treatment Market by Age Group

• Market Overview
• 0 to 18 Years
• 19 to 39 Years
• 40 to 64 Years
• 65 Years & Above

Onychomycosis Treatment Market by Gender

• Market Overview
• Male
• Female

Onychomycosis Treatment Market by Distribution Channel

• Market Overview
• Institutional Sales
  • Hospitals
  • Dermatology Clinics
• Retail Sales
  • Retail Pharmacies
  • Drug Stores
  • Mail Order Pharmacies & Online Sales

Onychomycosis Treatment Market Size by Region

• Market Overview
• North America
  • USA
  • Canada
• Europe
  • Germany
  • Spain
  • France
  • UK
  • Italy
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • South Korea
  • Rest of Asia-Pacific
• Latin America
  • Brazil
  • Rest of Latin America
• Middle East & Africa (MEA)
  • GCC Countries
  • South Africa
  • Rest of MEA

Competitive Landscape

• Top 5 Player Comparison
• Market Positioning of Key Players, 2023
• Strategies Adopted by Key Market Players
• Recent Activities in the Market
• Key Companies Market Share (%), 2023

Key Company Profiles

• Teva Pharmaceutical Industries Ltd. (Israel)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sanofi S.A. (France)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Medimetriks Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Galderma (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Johnson & Johnson (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Novartis AG (Switzerland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Moberg Pharma AB (Sweden)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cardinal Health, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Pfizer Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Almirall, S.A. (Spain)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Bayer AG (Germany)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Viatris Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• GlaxoSmithKline plc (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Cipla Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dr. Reddy's Laboratories Ltd. (India)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Evofem Biosciences, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Nabriva Therapeutics plc (Ireland)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Kaken Pharmaceutical Co., Ltd. (Japan)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Hikma Pharmaceuticals PLC (UK)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Dermavant Sciences, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Sientra, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments
• Zynerba Pharmaceuticals, Inc. (US)
  • Company Overview
  • Business Segment Overview
  • Financial Updates
  • Key Developments